← 產業報告目錄

Organ Preservation Market by Solution Type (UW, Custodial HTK, Perfadex), Technique (Static Cold Storage, Hypothermic, Normothermic), Organ (Kidneys, Liver, Heart), End User (Transplant Centers, Hospitals, Specialty Clinics) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-07-19頁數 235報告編號 MD4464

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global organ preservation market is projected to reach USD 0.3 billion by 2030 from USD 0.2 million in 2025, at a CAGR of 6.8% during the forecast period. The primary objective of organ preservation solutions and devices is to maintain the viability and functionality of organs between procurement and transplantation. Several factors fuel consistent growth in this market, including the increasing volume of organ transplants globally, technological advancements in preservation techniques, and the introduction of specialized solutions such as hypothermic and normothermic machine perfusion systems. The growing incidence of chronic diseases such as end-stage renal and liver failure is driving the demand for organ transplants, which in turn boosts the need for effective preservation technologies. By solution type, the University of Wisconsin (UW) segment accounted for the largest market share in 2024. The market is categorized into UW, Custodiol HTK, Perfadex, and other solutions by solution type. In 2024, the University of Wisconsin (UW) solution accounted for the largest market share owing to high adoption and features such as proven efficacy in preserving organs like the liver, kidneys, and pancreas. It was the first introduced intracellular preservation solution and is widely regarded as the global benchmark for organ preservation. Its established clinical outcomes and reliability have solidified its position as the preferred choice among transplant surgeons and healthcare facilities. By technique, the normothermic machine perfusion segment is expected to register the highest CAGR during the forecast period. The normothermic machine perfusion segment is expected to grow at the highest CAGR during the forecast period. This technique simulates natural physiological conditions by maintaining normal body temperature and supplying essential nutrients and oxygen to the organ. It supports cellular function and metabolism throughout the preservation period. Normothermic perfusion helps maintain organ viability and minimizes inflammatory responses and ischemic injury, particularly in liver transplants. It is vital in improving graft regeneration and has been associated with better outcomes in transplant cases involving extended criteria donors, such as older individuals or those with comorbidities. As a result, its relevance is growing among transplant professionals seeking to optimize long-term graft survival and function. By organ type, the lungs segment is expected to grow at the highest CAGR during the forecast period. The lungs segment is expected to grow at the highest CAGR during the forecast period. Lung transplantation is regarded as the preferred treatment for patients with end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, or cystic fibrosis, all of which contribute to the growth of this segment. Other common causes of end-stage lung disease in adult patients include alpha-1 antitrypsin deficiency and pulmonary hypertension. With the increasing prevalence of respiratory illnesses, the number of patients requiring lung transplants is anticipated to rise, thereby driving demand for lung transplants. Additionally, advancements in graft survival and long-term graft function have established lung transplantation as a vital and often life-saving therapeutic option. By end user, the specialty clinics segment is expected to grow at the highest CAGR during the forecast period. The organ preservation market is segmented by end-users into organ transplant centers, hospitals, and specialty clinics. The specialty clinics segment is projected to grow at the highest CAGR in the organ preservation market due to their increasing role in transplant procedures and post-operative care. These clinics offer focused expertise, faster turnaround times, and advanced technologies tailored to organ preservation needs. Additionally, growing patient preference for specialized care and the rise in private healthcare investments further accelerate their growth in this segment. By region, the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of this segment is primarily attributed to the combination of favorable government policies, increased public awareness, and a higher number of organ donations. For instance, China has seen its donation rates improve thanks to intensified public education, mobilization efforts, and technological advancements in organ transplants. Meanwhile, India's rapid development in healthcare infrastructure has supported market growth and fostered medical tourism. Even with religious considerations, Japan has observed an improvement in organ donation due to a higher willingness to donate organs. The breakdown of primary participants was as mentioned below: • By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20% • By Designation – C-level–35%, Director-level–25%, Others–40% • By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, the Middle East & Africa–1%, and GCC countries—1% Key Players in the Organ Preservation Market The key players operating in the organ preservation market include Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions (US), and TX Innovations (Netherlands). Research Coverage: The report analyzes the organ preservation market and aims to estimate the market size and future growth potential based on various segments such as solution, technique, organ type, end user, and region. The report also includes a product portfolio matrix of various organ preservation products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies. Reasons to Buy the Report The report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market. This report provides insights into the following pointers: Analysis of key drivers (Ascending cases of multiple organ failure and growth in the geriatric population, the increasing initiatives to promote public awareness and encourage organ donation, the rising number of organ donors boost adoption of solid organ transplantation procedures); restraints (High cost of organ transplantation and religious concerns and misconceptions associated to organ donation); opportunities (the increasing focus on healthcare investments); and challenges (Significant gap between the number of organs donated and organs required annually coupled with the development of artificial organs) • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global organ preservation market. The report analyzes this market by solution, technique, organ type, and end user. • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global organ preservation market • Market Development: Comprehensive information on the lucrative emerging markets by solution type, technique, organ type, and end user • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global organ preservation market • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global organ preservation market.
目錄 Table of Contents
1 INTRODUCTION 24 1.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 25 1.3 MARKET SCOPE 25 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 25 1.3.2 YEARS CONSIDERED 26 1.4 CURRENCY CONSIDERED 26 1.5 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH APPROACH 28 2.2 RESEARCH DESIGN 28 2.2.1 SECONDARY RESEARCH 29 2.2.1.1 Key data from secondary sources 30 2.2.2 PRIMARY DATA 30 2.2.2.1 Key data from primary sources 32 2.2.2.2 Key industry insights 33 2.3 MARKET SIZE ESTIMATION 35 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 41 2.5 MARKET RANKING ANALYSIS 42 2.6 RESEARCH ASSUMPTIONS 42 2.7 RESEARCH LIMITATIONS 42 2.7.1 METHODOLOGY-RELATED LIMITATIONS 42 2.7.2 SCOPE-RELATED LIMITATIONS 42 2.8 RISK ASSESSMENT 42 3 EXECUTIVE SUMMARY 43 4 PREMIUM INSIGHTS 47 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ORGAN PRESERVATION MARKET 47 4.2 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION AND COUNTRY 48 4.3 ORGAN PRESERVATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49 4.4 ORGAN PRESERVATION MARKET, BY REGION, 2023–2030 49 4.5 ORGAN PRESERVATION MARKET: DEVELOPED VS. EMERGING MARKETS 50   5 MARKET OVERVIEW 51 5.1 INTRODUCTION 51 5.2 MARKET DYNAMICS 51 5.2.1 DRIVERS 52 5.2.1.1 Growing geriatric population and subsequent growth in cases of multiple organ failure 52 5.2.1.2 Increasing initiatives to promote public awareness and encourage organ donation 52 5.2.1.3 Rising number of organ donors and growing adoption of solid organ transplantation procedures 53 5.2.2 RESTRAINTS 54 5.2.2.1 High cost of organ transplantation 54 5.2.2.2 Religious concerns and misconceptions associated with organ donation 54 5.2.3 OPPORTUNITIES 55 5.2.3.1 Growing healthcare investments 55 5.2.4 CHALLENGES 56 5.2.4.1 Significant gap between number of organs donated and organs required annually 56 5.2.4.2 Development of artificial organs 56 5.3 ECOSYSTEM ANALYSIS 57 5.4 VALUE CHAIN ANALYSIS 57 5.5 PRICING ANALYSIS 58 5.6 SUPPLY CHAIN ANALYSIS 59 5.7 PATENT ANALYSIS 60 5.7.1 PATENT PUBLICATION TRENDS FOR ORGAN PRESERVATION MARKET 60 5.7.2 TOP APPLICANTS (COMPANIES) OF ORGAN PRESERVATION PATENTS 61 5.7.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ORGAN PRESERVATION MARKET 61 5.8 TECHNOLOGY ANALYSIS 63 5.8.1 KEY TECHNOLOGIES 63 5.8.1.1 Machine perfusion 63 5.8.1.2 Organ perfusion 64 5.8.2 ADJACENT TECHNOLOGIES 64 5.8.2.1 Cryopreservation & vitrification 64 5.8.3 COMPLEMENTARY TECHNOLOGIES 64 5.8.3.1 Temperature monitoring devices 64 5.9 TRADE ANALYSIS 65 5.9.1 IMPORT DATA 65 5.9.2 EXPORT DATA 65 5.10 KEY CONFERENCES AND EVENTS IN 2025–2026 66   5.11 REGULATORY LANDSCAPE 66 5.11.1 REGULATORY ANALYSIS 66 5.11.1.1 North America 66 5.11.1.1.1 US 66 5.11.1.1.2 Canada 66 5.11.1.2 Europe 66 5.11.1.3 Asia Pacific 67 5.11.1.3.1 China 67 5.11.1.3.2 Japan 67 5.11.1.3.3 India 67 5.11.1.4 Latin America 67 5.11.1.4.1 Brazil 67 5.11.1.4.2 Mexico 68 5.11.1.5 Middle East 68 5.11.1.6 Africa 68 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 5.12 PORTER’S FIVE FORCES ANALYSIS 70 5.12.1 THREAT FROM NEW ENTRANTS 70 5.12.2 THREAT FROM SUBSTITUTES 71 5.12.3 BARGAINING POWER OF SUPPLIERS 71 5.12.4 BARGAINING POWER OF BUYERS 71 5.12.5 INTENSITY OF COMPETITIVE RIVALRY 71 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 72 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 72 5.13.2 BUYING CRITERIA 72 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 73 5.15 CASE STUDY ANALYSIS 74 5.16 INVESTMENT AND FUNDING SCENARIO 75 5.17 REIMBURSEMENT SCENARIO 75 5.18 IMPACT OF AI ON ORGAN PRESERVATION MARKET 76 5.19 END USER EXPECTATIONS IN ORGAN PRESERVATION MARKET 77 5.20 IMPACT OF 2025 US TARIFFS 78 5.20.1 INTRODUCTION 78 5.20.2 KEY TARIFF RATES 79 5.20.3 PRICE IMPACT ANALYSIS 79 5.20.4 IMPACT ON END USERS 80   6 ORGAN PRESERVATION MARKET, BY SOLUTION 81 6.1 INTRODUCTION 82 6.2 UNIVERSITY OF WISCONSIN 83 6.2.1 METABOLICALLY INERT SUBSTRATES ENABLE BETTER TRANSPLANTATION OUTCOMES 83 6.3 CUSTODIOL HTK 85 6.3.1 INDICATED FOR PERFUSION AND FLUSHING OF KIDNEYS, LIVER, PANCREAS, AND HEART 85 6.4 PERFADEX 86 6.4.1 LAUNCH OF PERFADEX PLUS TO DRIVE MARKET 86 6.5 OTHER SOLUTIONS 87 7 ORGAN PRESERVATION MARKET, BY TECHNIQUE 89 7.1 INTRODUCTION 90 7.2 STATIC COLD STORAGE 92 7.2.1 MOST WIDELY ADOPTED ORGAN PRESERVATION TECHNIQUE 92 7.3 HYPOTHERMIC MACHINE PERFUSION 94 7.3.1 ADVANTAGES ASSOCIATED WITH HYPOTHERMIC MACHINE PERFUSION TO DRIVE DEMAND 94 7.4 NORMOTHERMIC MACHINE PERFUSION 96 7.4.1 PROVIDES VIABLE ENVIRONMENT FOR ORGAN PRESERVATION, VIABILITY, AND REPAIR PRIOR TO TRANSPLANTATION 96 8 ORGAN PRESERVATION MARKET, BY ORGAN TYPE 98 8.1 INTRODUCTION 99 8.2 KIDNEYS 99 8.2.1 MOST TRANSPLANTED ORGANS GLOBALLY 99 8.3 LIVER 100 8.3.1 RISING PREVALENCE OF LIVER DISEASE AND GROWING CASES OF LIVER FAILURE TO DRIVE DEMAND FOR LIVER TRANSPLANTATION PROCEDURES 100 8.4 LUNGS 102 8.4.1 GROWTH IN COPD INCIDENCE TO BOOST DEMAND FOR PRESERVATION TECHNIQUES AND PRODUCTS 102 8.5 HEART 103 8.5.1 ADVANCEMENTS IN HEART PRESERVATION TECHNIQUES TO DRIVE MARKET 103 8.6 OTHER ORGANS 104 9 ORGAN PRESERVATION MARKET, BY END USER 106 9.1 INTRODUCTION 107 9.2 ORGAN TRANSPLANT CENTERS 107 9.2.1 MAJOR END USERS OF ORGAN PRESERVATION SOLUTIONS 107 9.3 HOSPITALS 108 9.3.1 INCREASING CASES OF ACCIDENTAL INJURIES AND CHRONIC DISEASES TO DRIVE MARKET 108 9.4 SPECIALTY CLINICS 110 9.4.1 INCREASING PREVALENCE OF END-STAGE DISEASES AND ORGAN FAILURE TO DRIVE MARKET 110 10 ORGAN PRESERVATION MARKET, BY REGION 111 10.1 INTRODUCTION 112 10.2 NORTH AMERICA 113 10.2.1 MACROECONOMIC OUTLOOK 113 10.2.2 US 116 10.2.2.1 Growing cases of organ failure and underlying diseases to drive demand 116 10.2.3 CANADA 119 10.2.3.1 Improved organ donation rates to drive growth 119 10.3 EUROPE 122 10.3.1 MACROECONOMIC OUTLOOK 122 10.3.2 GERMANY 125 10.3.2.1 Growing patient population to drive demand 125 10.3.3 FRANCE 127 10.3.3.1 Increasing number of organ transplants and organ donor registrations to drive growth 127 10.3.4 UK 129 10.3.4.1 Increasing disease/disorder prevalence and favorable regulations to drive demand 129 10.3.5 SPAIN 132 10.3.5.1 High donation rates to drive growth 132 10.3.6 ITALY 134 10.3.6.1 Surge in donor numbers and technological innovation to drive growth 134 10.3.7 REST OF EUROPE 136 10.4 ASIA PACIFIC 138 10.4.1 MACROECONOMIC OUTLOOK 139 10.4.2 CHINA 143 10.4.2.1 Growing awareness and adoption of laws favoring organ donation to drive market 143 10.4.3 JAPAN 145 10.4.3.1 Nationwide awareness campaigns and promoted opt-in registration to drive growth 145 10.4.4 INDIA 148 10.4.4.1 Growing number of initiatives to increase public awareness to drive market 148 10.4.5 AUSTRALIA 150 10.4.5.1 Enhanced hospital-based donation programs to drive growth 150 10.4.6 SOUTH KOREA 152 10.4.6.1 Improved donor registration systems to drive growth 152 10.4.7 REST OF ASIA PACIFIC 154 10.5 LATIN AMERICA 156 10.5.1 MACROECONOMIC OUTLOOK 157 10.5.2 BRAZIL 159 10.5.2.1 Digitalization of donor registries to drive growth 159 10.5.3 MEXICO 161 10.5.3.1 Organ donation efforts supported by centralized transplant registry and national coordination to drive growth 161 10.5.4 REST OF LATIN AMERICA 163 10.6 MIDDLE EAST & AFRICA 165 10.6.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES AND POLICIES TO DRIVE MARKET 165 10.6.2 MACROECONOMIC OUTLOOK 166 10.7 GCC COUNTRIES 168 10.7.1 STRONG ORGAN PRESERVATION THROUGH INCENTIVES, INFRASTRUCTURE, AND PUBLIC AWARENESS TO DRIVE GROWTH 168 10.7.2 MACROECONOMIC OUTLOOK 169 11 COMPETITIVE LANDSCAPE 172 11.1 OVERVIEW 172 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 172 11.3 REVENUE ANALYSIS, 2022–2024 174 11.4 MARKET SHARE ANALYSIS 175 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 177 11.5.1 STARS 177 11.5.2 EMERGING LEADERS 177 11.5.3 PERVASIVE PLAYERS 178 11.5.4 PARTICIPANTS 178 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 179 11.5.5.1 Company footprint 179 11.5.5.2 Solution footprint 180 11.5.5.3 Technique footprint 181 11.5.5.4 End user footprint 182 11.5.5.5 Region footprint 183 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 184 11.6.1 PROGRESSIVE COMPANIES 184 11.6.2 RESPONSIVE COMPANIES 184 11.6.3 DYNAMIC COMPANIES 184 11.6.4 STARTING BLOCKS 184 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 185 11.6.5.1 List of key startups/SMEs 185 11.6.5.2 Competitive benchmarking of key startups/SMEs 186   11.7 COMPANY VALUATION AND FINANCIAL METRICS 186 11.7.1 COMPANY VALUATION 186 11.7.2 FINANCIAL METRICS 187 11.8 BRAND/PRODUCT COMPARISON 187 11.9 COMPETITIVE SCENARIO 188 11.9.1 PRODUCT LAUNCHES & APPROVALS 188 11.9.2 DEALS 189 11.9.3 OTHER DEVELOPMENTS 190 12 COMPANY PROFILES 191 12.1 KEY PLAYERS 191 12.1.1 PARAGONIX TECHNOLOGIES, INC. 191 12.1.1.1 Business overview 191 12.1.1.2 Products offered 191 12.1.1.3 Recent developments 192 12.1.1.3.1 Product launches 192 12.1.1.3.2 Deals 193 12.1.1.3.3 Other developments 194 12.1.1.4 MnM view 194 12.1.1.4.1 Right to win 194 12.1.1.4.2 Strategic choices 194 12.1.1.4.3 Weaknesses and competitive threats 195 12.1.2 XVIVO PERFUSION AB 196 12.1.2.1 Business overview 196 12.1.2.2 Products offered 197 12.1.2.3 Recent developments 198 12.1.2.3.1 Product launches & approvals 198 12.1.2.3.2 Deals 199 12.1.2.4 MnM view 199 12.1.2.4.1 Right to win 199 12.1.2.4.2 Strategic choices 200 12.1.2.4.3 Weaknesses and competitive threats 200 12.1.3 DR. FRANZ KÖHLER CHEMIE GMBH 201 12.1.3.1 Business overview 201 12.1.3.2 Products offered 201 12.1.3.3 MnM view 202 12.1.3.3.1 Right to win 202 12.1.3.3.2 Strategic choices 202 12.1.3.3.3 Weaknesses and competitive threats 202   12.1.4 ESSENTIAL PHARMACEUTICALS, LLC (SUBSIDIARY OF ACCORD HEALTHCARE) 203 12.1.4.1 Business overview 203 12.1.4.2 Products offered 203 12.1.4.3 MnM view 204 12.1.4.3.1 Right to win 204 12.1.4.3.2 Strategic choices 204 12.1.4.3.3 Weaknesses and competitive threats 204 12.1.5 TRANSMEDICS, INC. 205 12.1.5.1 Business overview 205 12.1.5.2 Products offered 206 12.1.5.3 Recent developments 206 12.1.5.3.1 Product launches & approvals 206 12.1.5.3.2 Deals 206 12.1.5.4 MnM view 207 12.1.5.4.1 Right to win 207 12.1.5.4.2 Strategic choices 207 12.1.5.4.3 Weaknesses and competitive threats 207 12.1.6 ORGANOX LIMITED 208 12.1.6.1 Business overview 208 12.1.6.2 Products offered 208 12.1.6.3 Recent developments 208 12.1.6.3.1 Product launches & approvals 208 12.1.6.3.2 Deals 209 12.1.7 21ST CENTURY MEDICINE 210 12.1.7.1 Business overview 210 12.1.7.2 Products offered 210 12.1.8 BIOLIFE SOLUTIONS, INC. 211 12.1.8.1 Business overview 211 12.1.8.2 Products offered 212 12.1.8.3 Recent developments 212 12.1.8.3.1 Product launches 212 12.1.8.3.2 Deals 213 12.1.9 BRIDGE TO LIFE LIMITED 214 12.1.9.1 Business overview 214 12.1.9.2 Products offered 214 12.1.9.3 Recent developments 215 12.1.9.3.1 Product launches & approvals 215 12.1.9.3.2 Deals 215 12.1.10 WATERS MEDICAL SYSTEMS LLC 216 12.1.10.1 Business overview 216 12.1.10.2 Products offered 216   12.2 OTHER PLAYERS 217 12.2.1 SHANGHAI GENEXT MEDICAL TECHNOLOGY CO., LTD. 217 12.2.2 PRESERVATION SOLUTIONS, INC. 218 12.2.3 CARNAMEDICA 219 12.2.4 TRANSPLANT BIOMEDICALS 220 12.2.5 INSTITUT GEORGES LOPEZ 221 12.2.6 GLOBAL TRANSPLANT SOLUTIONS 222 12.2.7 AVIONORD 222 12.2.8 ORGAN PRESERVATION SOLUTIONS LTD. 223 12.2.9 EBERS 223 12.2.10 S.A.L.F. 224 12.2.11 BIOCHEFA 224 12.2.12 VASCULAR PERFUSION SOLUTIONS, INC. 225 12.2.13 TX INNOVATIONS 225 12.2.14 TAIYO NIPPON SANSO CORPORATION 226 12.2.15 X-THERMA, INC. 226 13 APPENDIX 227 13.1 DISCUSSION GUIDE 227 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 231 13.3 AVAILABLE CUSTOMIZATIONS 233 13.4 RELATED REPORTS 233 13.5 AUTHOR DETAILS 234
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD, 2021–2024 26 TABLE 2 GROWTH IN GERIATRIC POPULATION (ABOVE 65 AGE GROUP), BY REGION, 2019 VS. 2050 (MILLION) 52 TABLE 3 NUMBER OF ORGAN DONATIONS, 2020 54 TABLE 4 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD) 55 TABLE 5 AVERAGE SELLING PRICE RANGE OF ORGAN PRESERVATION SOLUTIONS, BY KEY PLAYERS, 2023–2024 58 TABLE 6 AVERAGE SELLING PRICE RANGE OF CUSTODIOL SOLUTIONS FOR ORGAN PRESERVATION SOLUTIONS IN KEY REGIONS, 2022–2024 59 TABLE 7 ORGAN PRESERVATION MARKET: LIST OF MAJOR PATENTS, 2020–2021 62 TABLE 8 IMPORT DATA OF ORGAN PRESERVATION FOR HS CODE 300640, BY COUNTRY, 2019–2023 (USD THOUSAND) 65 TABLE 9 EXPORT DATA OF ORGAN PRESERVATION FOR HS CODE 300640, BY COUNTRY, 2019–2023 (USD THOUSAND) 65 TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS (%) 72 TABLE 15 KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS 73 TABLE 16 CASE STUDY 1: PRESERVATION OF MARGINAL LIVER USING NORMOTHERMIC MACHINE PERFUSION (NMP) 74 TABLE 17 CASE STUDY 2: HYPOTHERMIC MACHINE PERFUSION FOR EXTENDED CRITERIA KIDNEY TRANSPLANT 74 TABLE 18 CASE STUDY 3: USE OF PORTABLE NORMOTHERMIC PERFUSION FOR HEART TRANSPLANTATION 75 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 79 TABLE 20 ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 82 TABLE 21 ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 83 TABLE 22 ORGAN PRESERVATION MARKET FOR UW SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 84 TABLE 23 ORGAN PRESERVATION MARKET FOR CUSTODIOL HTK SOLUTIONS, BY COUNTRY/ REGION, 2023–2030 (USD MILLION) 86 TABLE 24 ORGAN PRESERVATION MARKET FOR PERFADEX SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 87 TABLE 25 OTHER ORGAN PRESERVATION SOLUTIONS MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 88 TABLE 26 COMPARISON OF METHODS USED FOR ORGAN PRESERVATION 90 TABLE 27 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 90 TABLE 28 ORGAN PRESERVATION TECHNIQUE MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 91 TABLE 29 STATIC COLD STORAGE: ADVANTAGES AND DISADVANTAGES 92 TABLE 30 ORGAN PRESERVATION MARKET FOR STATIC COLD STORAGE, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 93 TABLE 31 HYPOTHERMIC MACHINE PERFUSION: ADVANTAGES AND DISADVANTAGES 94 TABLE 32 ORGAN PRESERVATION MARKET FOR HYPOTHERMIC MACHINE PERFUSION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 95 TABLE 33 NORMOTHERMIC MACHINE PERFUSION: ADVANTAGES AND DISADVANTAGES 96 TABLE 34 ORGAN PRESERVATION MARKET FOR NORMOTHERMIC MACHINE PERFUSION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 97 TABLE 35 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 99 TABLE 36 KIDNEY PRESERVATION MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 100 TABLE 37 LIVER PRESERVATION MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 101 TABLE 38 LUNG PRESERVATION MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 103 TABLE 39 HEART PRESERVATION MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 104 TABLE 40 OTHER ORGAN PRESERVATION MARKET, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 105 TABLE 41 ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 107 TABLE 42 ORGAN PRESERVATION MARKET FOR ORGAN TRANSPLANT CENTERS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 108 TABLE 43 ORGAN PRESERVATION MARKET FOR HOSPITALS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 109 TABLE 44 ORGAN PRESERVATION MARKET FOR SPECIALTY CLINICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 110 TABLE 45 ORGAN PRESERVATION MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 46 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 47 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 115 TABLE 48 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 115 TABLE 49 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 116 TABLE 50 NORTH AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 116 TABLE 51 US: KEY MACROINDICATORS 117 TABLE 52 WAITING LIST FOR ORGAN TRANSPLANTS AS OF JANUARY 2022 117 TABLE 53 US: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 118 TABLE 54 US: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 118 TABLE 55 US: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 119 TABLE 56 US: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 119 TABLE 57 CANADA: KEY MACROINDICATORS 120 TABLE 58 CANADA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 120 TABLE 59 CANADA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 121 TABLE 60 CANADA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 121 TABLE 61 CANADA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 121 TABLE 62 EUROPE: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 63 EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 123 TABLE 64 EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 124 TABLE 65 EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 124 TABLE 66 EUROPE: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 125 TABLE 67 GERMANY: KEY MACROINDICATORS 126 TABLE 68 GERMANY: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 126 TABLE 69 GERMANY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 126 TABLE 70 GERMANY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 127 TABLE 71 GERMANY: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 127 TABLE 72 FRANCE: KEY MACROINDICATORS 128 TABLE 73 FRANCE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 128 TABLE 74 FRANCE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 128 TABLE 75 FRANCE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 129 TABLE 76 FRANCE: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 129 TABLE 77 UK: KEY MACROINDICATORS 130 TABLE 78 TOTAL NUMBER OF PATIENTS ON ACTIVE ORGAN TRANSPLANT WAITING LIST IN UK (AS OF APRIL 8, 2021) 130 TABLE 79 UK: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 130 TABLE 80 UK: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 131 TABLE 81 UK: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 131 TABLE 82 UK: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 131 TABLE 83 SPAIN: KEY MACROINDICATORS 132 TABLE 84 SPAIN: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 132 TABLE 85 SPAIN: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 133 TABLE 86 SPAIN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 133 TABLE 87 SPAIN: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 134 TABLE 88 ITALY: KEY MACROINDICATORS 134 TABLE 89 ITALY: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 135 TABLE 90 ITALY: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 135 TABLE 91 ITALY: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 136 TABLE 92 ITALY: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 136 TABLE 93 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 137 TABLE 94 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 137 TABLE 95 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 138 TABLE 96 REST OF EUROPE: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 138 TABLE 97 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 98 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 141 TABLE 99 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 142 TABLE 100 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 142 TABLE 101 ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 143 TABLE 102 CHINA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 144 TABLE 103 CHINA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 144 TABLE 104 CHINA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 145 TABLE 105 CHINA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 145 TABLE 106 TOTAL NUMBER OF PATIENTS ON ORGAN TRANSPLANT WAITING LIST IN JAPAN (AS OF MARCH 31, 2021) 146 TABLE 107 JAPAN: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 146 TABLE 108 JAPAN: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 147 TABLE 109 JAPAN: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 147 TABLE 110 JAPAN: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 148 TABLE 111 INDIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 149 TABLE 112 INDIA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 149 TABLE 113 INDIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 150 TABLE 114 INDIA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 150 TABLE 115 AUSTRALIA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 151 TABLE 116 AUSTRALIA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 151 TABLE 117 AUSTRALIA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 152 TABLE 118 AUSTRALIA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 152 TABLE 119 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 153 TABLE 120 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 153 TABLE 121 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 154 TABLE 122 SOUTH KOREA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 154 TABLE 123 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 155 TABLE 124 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 155 TABLE 125 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 156 TABLE 126 REST OF ASIA PACIFIC: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 156 TABLE 127 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 128 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 158 TABLE 129 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 158 TABLE 130 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 159 TABLE 131 LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 159 TABLE 132 BRAZIL: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 160 TABLE 133 BRAZIL: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 160 TABLE 134 BRAZIL: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 161 TABLE 135 BRAZIL: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 161 TABLE 136 MEXICO: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 162 TABLE 137 MEXICO: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 162 TABLE 138 MEXICO: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 163 TABLE 139 MEXICO: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 163 TABLE 140 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 164 TABLE 141 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 164 TABLE 142 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 165 TABLE 143 REST OF LATIN AMERICA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 165 TABLE 144 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 166 TABLE 145 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 167 TABLE 146 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 167 TABLE 147 MIDDLE EAST & AFRICA: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 148 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2023–2030 (USD MILLION) 169 TABLE 149 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY SOLUTION, 2023–2030 (USD MILLION) 170 TABLE 150 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2023–2030 (USD MILLION) 170 TABLE 151 GCC COUNTRIES: ORGAN PRESERVATION MARKET, BY END USER, 2023–2030 (USD MILLION) 171 TABLE 152 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORGAN PRESERVATION MARKET 173 TABLE 153 ORGAN PRESERVATION MARKET: DEGREE OF COMPETITION 176 TABLE 154 ORGAN PRESERVATION MARKET: SOLUTION FOOTPRINT 180 TABLE 155 ORGAN PRESERVATION MARKET: TECHNIQUE FOOTPRINT 181 TABLE 156 ORGAN PRESERVATION MARKET: END USER FOOTPRINT 182 TABLE 157 ORGAN PRESERVATION MARKET: REGION FOOTPRINT 183 TABLE 158 ORGAN PRESERVATION MARKET: LIST OF KEY STARTUPS/SMES 185 TABLE 159 ORGAN PRESERVATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 186 TABLE 160 ORGAN PRESERVATION MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JUNE 2025 188 TABLE 161 ORGAN PRESERVATION MARKET: DEALS, JANUARY 2021–JUNE 2025 189 TABLE 162 ORGAN PRESERVATION MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JUNE 2025 190 TABLE 163 PARAGONIX TECHNOLOGIES, INC.: COMPANY OVERVIEW 191 TABLE 164 PARAGONIX TECHNOLOGIES, INC.: PRODUCTS OFFERED 191 TABLE 165 PARAGONIX TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 192 TABLE 166 PARAGONIX TECHNOLOGIES, INC.: DEALS, JANUARY 2021–MAY 2025 193 TABLE 167 PARAGONIX TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2025 194 TABLE 168 XVIVO PERFUSION AB: COMPANY OVERVIEW 196 TABLE 169 XVIVO PERFUSION AB: PRODUCTS OFFERED 197 TABLE 170 XVIVO PERFUSION AB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 198 TABLE 171 XVIVO PERFUSION AB: DEALS, JANUARY 2021–MAY 2025 199 TABLE 172 DR. FRANZ KÖHLER CHEMIE GMBH: COMPANY OVERVIEW 201 TABLE 173 DR. FRANZ KÖHLER CHEMIE GMBH: PRODUCTS OFFERED 201 TABLE 174 ESSENTIAL PHARMACEUTICALS, LLC: COMPANY OVERVIEW 203 TABLE 175 ESSENTIAL PHARMACEUTICALS, LLC: PRODUCTS OFFERED 203 TABLE 176 TRANSMEDICS, INC.: COMPANY OVERVIEW 205 TABLE 177 TRANSMEDICS, INC.: PRODUCTS OFFERED 206 TABLE 178 TRANSMEDICS, INC.: PRODUCT LAUNCHES & APPROVALS 206 TABLE 179 TRANSMEDICS, INC.: DEALS 206 TABLE 180 ORGANOX LIMITED: COMPANY OVERVIEW 208 TABLE 181 ORGANOX LIMITED: PRODUCTS OFFERED 208 TABLE 182 ORGANOX LIMITED: PRODUCT LAUNCHES & APPROVALS 208 TABLE 183 ORGANOX LIMITED: DEALS 209 TABLE 184 21ST CENTURY MEDICINE: COMPANY OVERVIEW 210 TABLE 185 21ST CENTURY MEDICINE: PRODUCTS OFFERED 210 TABLE 186 BIOLIFE SOLUTIONS, INC.: COMPANY OVERVIEW 211 TABLE 187 BIOLIFE SOLUTIONS, INC.: PRODUCTS OFFERED 212 TABLE 188 BIOLIFE SOLUTIONS, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 212 TABLE 189 BIOLIFE SOLUTIONS, INC.: DEALS, JANUARY 2021–MAY 2025 213 TABLE 190 BRIDGE TO LIFE LIMITED: COMPANY OVERVIEW 214 TABLE 191 BRIDGE TO LIFE LIMITED: PRODUCTS OFFERED 214 TABLE 192 BRIDGE TO LIFE LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 215 TABLE 193 BRIDGE TO LIFE LIMITED: DEALS, JANUARY 2021–MAY 2025 215 TABLE 194 WATERS MEDICAL SYSTEMS LLC: COMPANY OVERVIEW 216 TABLE 195 WATERS MEDICAL SYSTEMS LLC: PRODUCTS OFFERED 216 FIGURE 1 ORGAN PRESERVATION MARKET: RESEARCH DESIGN 28 FIGURE 2 LIST OF PRIMARY SOURCES 31 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 33 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 34 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 34 FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 35 FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: XVIVO PERFUSION AB (2024) 36 FIGURE 8 ILLUSTRATIVE EXAMPLE OF PROCEDURE-BASED MARKET ESTIMATION 37 FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: ORGAN PRESERVATION MARKET (2024) 38 FIGURE 10 TOP-DOWN APPROACH 38 FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORGAN PRESERVATION MARKET (2025–2030) 39 FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40 FIGURE 13 DATA TRIANGULATION METHODOLOGY 41 FIGURE 14 ORGAN PRESERVATION MARKET, BY SOLUTION, 2025 VS. 2030 (USD MILLION) 43 FIGURE 15 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION) 44 FIGURE 16 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2025 VS. 2030 (USD MILLION) 44 FIGURE 17 ORGAN PRESERVATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 45 FIGURE 18 GEOGRAPHIC ANALYSIS OF ORGAN PRESERVATION MARKET 46 FIGURE 19 RISING NUMBER OF SOLID ORGAN TRANSPLANTS TO DRIVE ORGAN PRESERVATION MARKET 47 FIGURE 20 UNIVERSITY OF WISCONSIN SOLUTION AND CHINA SEGMENTS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ORGAN PRESERVATION MARKET IN 2024 48 FIGURE 21 CHINA TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD 49 FIGURE 22 NORTH AMERICA TO DOMINATE ORGAN PRESERVATION MARKET TILL 2030 49 FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 50 FIGURE 24 ORGAN PRESERVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 FIGURE 25 ORGAN PRESERVATION MARKET: ECOSYSTEM ANALYSIS 57 FIGURE 26 ORGAN PRESERVATION MARKET: VALUE CHAIN ANALYSIS 58 FIGURE 27 SUPPLY CHAIN ANALYSIS: ORGAN PRESERVATION MARKET (2024) 59 FIGURE 28 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR ORGAN PRESERVATION SOLUTIONS (JANUARY 2014–APRIL 2025) 61 FIGURE 29 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ORGAN PRESERVATION PATENTS, 2014–2025 61 FIGURE 30 ORGAN PRESERVATION MARKET: PORTER’S FIVE FORCES ANALYSIS 70 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS 72 FIGURE 32 KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS 72 FIGURE 33 TRENDS AND DISRUPTIONS DISRUPTING CUSTOMER BUSINESS IN ORGAN PRESERVATION MARKET 73 FIGURE 34 ORGAN PRESERVATION MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2024 75 FIGURE 35 ORGAN PRESERVATION MARKET: AI INTEGRATION 77 FIGURE 38 ASIA PACIFIC: ORGAN PRESERVATION MARKET SNAPSHOT 140 FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN ORGAN PRESERVATION MARKET (2021−2024) 175 FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 175 FIGURE 41 ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 178 FIGURE 42 ORGAN PRESERVATION MARKET: COMPANY FOOTPRINT 179 FIGURE 43 ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 185 FIGURE 44 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 186 FIGURE 45 EV/EBITDA OF KEY VENDORS 187 FIGURE 46 ORGAN PRESERVATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 187 FIGURE 47 XVIVO PERFUSION AB: COMPANY SNAPSHOT (2024) 197 FIGURE 48 TRANSMEDICS, INC.: COMPANY SNAPSHOT (2024) 205 FIGURE 49 BIOLIFE SOLUTIONS, INC.: COMPANY SNAPSHOT (2024) 211 FIGURE 1 ORGAN PRESERVATION MARKET: RESEARCH DESIGN 28 FIGURE 2 LIST OF PRIMARY SOURCES 31 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 33 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 34 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 34 FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 35 FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: XVIVO PERFUSION AB (2024) 36 FIGURE 8 ILLUSTRATIVE EXAMPLE OF PROCEDURE-BASED MARKET ESTIMATION 37 FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: ORGAN PRESERVATION MARKET (2024) 38 FIGURE 10 TOP-DOWN APPROACH 38 FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORGAN PRESERVATION MARKET (2025–2030) 39 FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40 FIGURE 13 DATA TRIANGULATION METHODOLOGY 41 FIGURE 14 ORGAN PRESERVATION MARKET, BY SOLUTION, 2025 VS. 2030 (USD MILLION) 43 FIGURE 15 ORGAN PRESERVATION MARKET, BY TECHNIQUE, 2025 VS. 2030 (USD MILLION) 44 FIGURE 16 ORGAN PRESERVATION MARKET, BY ORGAN TYPE, 2025 VS. 2030 (USD MILLION) 44 FIGURE 17 ORGAN PRESERVATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 45 FIGURE 18 GEOGRAPHIC ANALYSIS OF ORGAN PRESERVATION MARKET 46 FIGURE 19 RISING NUMBER OF SOLID ORGAN TRANSPLANTS TO DRIVE ORGAN PRESERVATION MARKET 47 FIGURE 20 UNIVERSITY OF WISCONSIN SOLUTION AND CHINA SEGMENTS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ORGAN PRESERVATION MARKET IN 2024 48 FIGURE 21 CHINA TO REGISTER FASTEST GROWTH DURING FORECAST PERIOD 49 FIGURE 22 NORTH AMERICA TO DOMINATE ORGAN PRESERVATION MARKET TILL 2030 49 FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 50 FIGURE 24 ORGAN PRESERVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 FIGURE 25 ORGAN PRESERVATION MARKET: ECOSYSTEM ANALYSIS 57 FIGURE 26 ORGAN PRESERVATION MARKET: VALUE CHAIN ANALYSIS 58 FIGURE 27 SUPPLY CHAIN ANALYSIS: ORGAN PRESERVATION MARKET (2024) 59 FIGURE 28 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR ORGAN PRESERVATION SOLUTIONS (JANUARY 2014–APRIL 2025) 61 FIGURE 29 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ORGAN PRESERVATION PATENTS, 2014–2025 61 FIGURE 30 ORGAN PRESERVATION MARKET: PORTER’S FIVE FORCES ANALYSIS 70 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 SOLUTIONS 72 FIGURE 32 KEY BUYING CRITERIA FOR TOP 3 SOLUTIONS 72 FIGURE 33 TRENDS AND DISRUPTIONS DISRUPTING CUSTOMER BUSINESS IN ORGAN PRESERVATION MARKET 73 FIGURE 34 ORGAN PRESERVATION MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2024 75 FIGURE 35 ORGAN PRESERVATION MARKET: AI INTEGRATION 77 FIGURE 38 ASIA PACIFIC: ORGAN PRESERVATION MARKET SNAPSHOT 140 FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN ORGAN PRESERVATION MARKET (2021−2024) 175 FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS (2024) 175 FIGURE 41 ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 178 FIGURE 42 ORGAN PRESERVATION MARKET: COMPANY FOOTPRINT 179 FIGURE 43 ORGAN PRESERVATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 185 FIGURE 44 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS 186 FIGURE 45 EV/EBITDA OF KEY VENDORS 187 FIGURE 46 ORGAN PRESERVATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 187 FIGURE 47 XVIVO PERFUSION AB: COMPANY SNAPSHOT (2024) 197 FIGURE 48 TRANSMEDICS, INC.: COMPANY SNAPSHOT (2024) 205 FIGURE 49 BIOLIFE SOLUTIONS, INC.: COMPANY SNAPSHOT (2024) 211

同分類最新報告(醫療器材)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們